Overview

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Status:
Unknown status

Trial end date:
2020-03-01

Target enrollment:

Participant gender:

Summary

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure refractory anemia with excess blasts-1 (RAEB-1), refractory anemia with excess blasts-2 (RAEB-2) and acute myeloid leukemia (AML) secondary to myelodysplastic syndrome (MDS). At present, the best conditioning regimen for RAEB-1, RAEB-2 and AML secondary to MDS undergoing allo-HSCT remains in discussion. In this prospective randomized controlled study, the safety and efficacy of G-CSF+ Decitabine + BUCY and BUCY myeloablative conditioning regimens in patients with RAEB-1, REAB-2 and AML Secondary to MDS undergoing allo-HSCT are evaluated.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Nanfang Hospital of Southern Medical University

Collaborators:

Guangzhou First People's Hospital
Peking University People's Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
Third Affiliated Hospital, Sun Yat-Sen University
Zhujiang Hospital

Treatments:

Azacitidine
Busulfan
Cyclophosphamide
Decitabine
Lenograstim
Sargramostim